Diabetes and Dyslipidaemia: optimising treatment to reduce cardiovascular risk
Atherosclerotic cardiovascular disease is one of the leading causes of death in people living with Type 2 diabetes. Dyslipidaemia is one of the major risk factors for developing cardiovascular disease, and it is estimated that up to two-thirds of individuals living with Type 2 Diabetes have evidence of dyslipidaemia.
There is an established relationship between LDL-cholesterol (LDL-C) levels and risk of major cardiovascular events. A growing evidence base has driven a reduction of recommended target LDL-C levels over time for people at high risk of cardiovascular disease including people living with Type 2 diabetes. However, LDL-C target attainment is lowest among those at high CV risk.
Statins remain the cornerstone of LDL-C lowering, however several additional lipid-lowering therapies are now available and combination lipid-lowering therapy is increasingly the norm to achieve these tight LDL-C targets for those at high risk of CVD.
Our webinar sessions on diabetes and dyslipidaemia will explore the link between Type 2 diabetes and cardiovascular disease, covering epidemiology and risk stratification through to latests evidence, guidelines and treatments to improve outcomes for patients.
Webinar 1: Tuesday 24 September 12-2pm (BST)
There will be two 40-minute presentations followed by 30 minutes discussion and Q&A where the audience will have the opportunity to ask questions to the speakers.
The session will be chaired by Dr Kevin Fernando, GP North Berwick Health Centre
Presentation 1: Atherosclerotic cardiovascular disease and Type 2 Diabetes: Epidemiology, Pathophysiology, Risk Stratification and a Call to Action
Speaker: Kevin Fernando, GP
Presentation 2: The LDL-cholesterol hypothesis: what is the relationship between LDL-C levels and risk of major CV events?
Speaker: Derek Connolly, Consultant Cardiologist
Webinar 2: Wednesday 30 October 12-2pm (GMT)
There will be two 40-minute presentations followed by 30 minutes discussion and Q&A where the audience will have the opportunity to ask questions to the speakers.
The session will be chaired by Dr Kevin Fernando, GP North Berwick Health Centre
Presentation 1: National & international lipid guidance: definition of total CV risk in people living with Type 2 Diabetes and recommended treatment goals for LDL-C lowering therapy
Speaker: Niraj Lakhani, Pharmacist
Presentation 2: National & international lipid guidance: current recommendations for lipid-lowering therapies for people living with Type 2 Diabetes
Speaker: Mrs Beverley Bostock, Advanced Nurse Practitioner